Nura Bio has secured an additional $68m in a Series A financing round to advance the development of its neuroprotective therapies.
The latest funding brings the total funds raised by the company to more than $140m with $73m in an initial Series A round in 2020.
The Column Group led the investment round, with continued support from Samsara Bio Capital and Euclidean Capital, and new backing from Sanofi Ventures.
Nura Bio’s recent funding milestone coincides with the successful completion of Phase I studies for its lead clinical candidate, NB-4746, in healthy subjects.
A brain-penetrant SARM1 inhibitor, NB-4746 has demonstrated potential in preventing axon degeneration and offering neuroprotection in preclinical models of nerve injury and disease.
The Phase I trial data indicated that NB-4746 was well-tolerated in both single ascending and multiple ascending dose arms, achieving targeted plasma exposure levels believed to be necessary for efficacy without serious treatment-emergent adverse events.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Cerebrospinal fluid levels of NB-4746 confirmed brain penetration, bolstering the molecule’s prospects for treating conditions impacting the peripheral and central nervous systems.
The company is preparing to commence a Phase Ib/II trial with NB-4746 in patients by 2025.
In conjunction with the latest funding, the company appointed Shilpa Sambashivan as its new CEO and board member.
Dr Sambashivan stated: “At Nura Bio, we have been laser-focused on our mission of delivering novel neuroprotective therapies to patients by leveraging our deep scientific understanding of underlying disease mechanisms including axon degeneration and neuroinflammation. The strong support demonstrated by our investors through this financing reflects the tremendous potential of our research and development pipeline.
“I am proud of the results our team has delivered. I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025 with our lead candidate NB-4746 while continuing to advance our promising preclinical pipeline.”
